Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Inclusion criteria

• Participants must be at least 16 years of age or older at the time of signing the informed consent/assent.
• Source-verified kidney biopsy confirmed diagnosis of IgAN.
• Participant has estimated glomerular filtration rate (eGFR) > 45 mL/min/1.73 m2 using serum creatinine (Chronic Kidney Disease-Epidemiology Collaboration [CKD EPI] creatinine eGFR 2021 equation for those 18 years and older; Chronic Kidney Disease in Children under age 25 [CKiD U25] eGFR equation for those younger than 18 years)

Exclusion criteria

• Participants who are breast-feeding and/or who have a positive pregnancy test result prior to receiving sibeprenlimab.
• Participant has coexisting chronic kidney disease, other than IgAN.
• Participant has a serum IgG value <600 mg/dL at screening.
• Participant is currently receiving or has received within 24 weeks prior to the firstdose of sibeprenlimab, systemic corticosteroids or immunosuppression (note:

topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids are allowed).

• Participant has uncontrolled hypertension (defined as systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg).
• Participants who would be likely to require prohibited concomitant therapy during the trial.